These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 21710476)
1. Treatment implication from the potential association between nonalcoholic fatty liver disease and cardiovascular disease. Shen L Hepatology; 2011 Jul; 54(1):377-8. PubMed ID: 21710476 [No Abstract] [Full Text] [Related]
2. [The association of cardiovascular risk factors with nonalcoholic fatty liver disease in health checkup examinees]. Yu JH; Lee KS; Lee SY; Hong AR; Park YS J Prev Med Public Health; 2008 Nov; 41(6):407-12. PubMed ID: 19037170 [TBL] [Abstract][Full Text] [Related]
3. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Marchesini G; Moscatiello S; Agostini F; Villanova N; Festi D Expert Opin Emerg Drugs; 2011 Mar; 16(1):121-36. PubMed ID: 21352073 [TBL] [Abstract][Full Text] [Related]
4. [News from the Cochrane Library: treatment of nonalcoholic fatty liver disease and steatohepatitis]. Timmer A Z Gastroenterol; 2007 Feb; 45(2):191-3. PubMed ID: 17304406 [No Abstract] [Full Text] [Related]
5. [Advisability of using probiotics in the treatment of atherogenic dyslipidemia]. Zvenigorodskaia LA; Cherkashova EA; Samsonova NG; Nilova TV; Sil'verstova SIu Eksp Klin Gastroenterol; 2011; (2):37-43. PubMed ID: 21563361 [TBL] [Abstract][Full Text] [Related]
7. Suggestion of a dual-functional agent for future trials in nonalcoholic fatty liver disease. Shen L Hepatology; 2010 Nov; 52(5):1866-7. PubMed ID: 20672381 [No Abstract] [Full Text] [Related]
8. Citrus auraptene: a potential multifunctional therapeutic agent for nonalcoholic fatty liver disease. Sahebkar A Ann Hepatol; 2011; 10(4):575-7. PubMed ID: 21911903 [No Abstract] [Full Text] [Related]
9. [Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for the patients with nonalcoholic fatty liver disease]. Su HL; Zhu YX; Gao ZJ; Dong XY; Zhu JY; Lei WR; Zhang Y; Han Y Zhonghua Gan Zang Bing Za Zhi; 2011 Jul; 19(7):552-3. PubMed ID: 22152250 [No Abstract] [Full Text] [Related]
10. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Edens MA; Kuipers F; Stolk RP Obes Rev; 2009 Jul; 10(4):412-9. PubMed ID: 19413701 [TBL] [Abstract][Full Text] [Related]
18. Orlistat in the treatment of NASH: a case series. Harrison SA; Ramrakhiani S; Brunt EM; Anbari MA; Cortese C; Bacon BR Am J Gastroenterol; 2003 Apr; 98(4):926-30. PubMed ID: 12738478 [TBL] [Abstract][Full Text] [Related]
19. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. Targher G; Day CP; Bonora E N Engl J Med; 2010 Sep; 363(14):1341-50. PubMed ID: 20879883 [No Abstract] [Full Text] [Related]
20. Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine. Patrick L Altern Med Rev; 2002 Aug; 7(4):276-91. PubMed ID: 12197781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]